Abattis Bioceuticals Corp Stock Probability of Future Pink Sheet Price Finishing Over 1.0E-4
| ATTBF Stock | USD 0.0001 0.00 0.00% |
Abattis |
Abattis Bioceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Abattis Bioceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Abattis Bioceuticals Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Abattis Bioceuticals generated a negative expected return over the last 90 days | |
| Abattis Bioceuticals has some characteristics of a very speculative penny stock | |
| Abattis Bioceuticals Corp has accumulated 150.86 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Abattis Bioceuticals Corp has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Abattis Bioceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Abattis Bioceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abattis Bioceuticals Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abattis to invest in growth at high rates of return. When we think about Abattis Bioceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 356.88 K. Net Loss for the year was (3.04 M) with profit before overhead, payroll, taxes, and interest of 241.34 K. |
Abattis Bioceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Abattis Pink Sheet often depends not only on the future outlook of the current and potential Abattis Bioceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Abattis Bioceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 477.8 M |
Abattis Bioceuticals Technical Analysis
Abattis Bioceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Abattis Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Abattis Bioceuticals Corp. In general, you should focus on analyzing Abattis Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Abattis Bioceuticals Predictive Forecast Models
Abattis Bioceuticals' time-series forecasting models is one of many Abattis Bioceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Abattis Bioceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Abattis Bioceuticals Corp
Checking the ongoing alerts about Abattis Bioceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Abattis Bioceuticals Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Abattis Bioceuticals generated a negative expected return over the last 90 days | |
| Abattis Bioceuticals has some characteristics of a very speculative penny stock | |
| Abattis Bioceuticals Corp has accumulated 150.86 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Abattis Bioceuticals Corp has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Abattis Bioceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Abattis Bioceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abattis Bioceuticals Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abattis to invest in growth at high rates of return. When we think about Abattis Bioceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 356.88 K. Net Loss for the year was (3.04 M) with profit before overhead, payroll, taxes, and interest of 241.34 K. |
Other Information on Investing in Abattis Pink Sheet
Abattis Bioceuticals financial ratios help investors to determine whether Abattis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abattis with respect to the benefits of owning Abattis Bioceuticals security.